Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
Carol Moreno(Universitat Autònoma de Barcelona), Richard Greil(Paracelsus Medical University), Fatih Demırkan(Dokuz Eylül University), Alessandra Tedeschi(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Bertrand Anz(Tennessee Oncology), Loree Larratt(University of Alberta), Martin Šimkovič(University Hospital Hradec Králové), Olga Samoilova(Nizhny Novgorod Regional Clinical Hospital named after Semashko), Jan Novák(Charles University), Dina Ben‐Yehuda(Hadassah Medical Center), Владимир Стругов(Federal Almazov North-West Medical Research Centre), Devinder Gill(Princess Alexandra Hospital), John G. Gribben(Queen Mary University of London), Emily Hsu(AbbVie (United States)), Chih‐Jian Lih(Pharmacyclics (United States)), Cathy Zhou(Pharmacyclics (United States)), Fong Clow(AbbVie (United States)), Danelle F. James(AbbVie (United States)), Lori Styles(Pharmacyclics (United States)), Ian W. Flinn(Sarah Cannon)
Cited by 546
Abstract
Related Papers
No related papers found
Powered by citation graph analysis